<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515459</url>
  </required_header>
  <id_info>
    <org_study_id>20 SARC 03</org_study_id>
    <nct_id>NCT04515459</nct_id>
  </id_info>
  <brief_title>Efficacy of Pre-operative Prehabilitation in Patients With Limb Sarcoma</brief_title>
  <acronym>EPOP-SARCOMA</acronym>
  <official_title>Efficacy of Pre-operative Prehabilitation in Patients With Limb Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II feasibility study, prospective, interventional, monocentric aiming to assess&#xD;
      the interest of pre-operative rehabilitation in patients treated for bone or soft-tissue&#xD;
      sarcoma of the limbs.&#xD;
&#xD;
      This protocol will be based on the realisation of a surgical prehabilitation program adapted&#xD;
      to the patient. This strategy will involve a team of several health professionals:&#xD;
      rehabilitation doctor, physiotherapist, occupational therapist, specialised nurse, dietician&#xD;
      and adapted physical activity teacher.&#xD;
&#xD;
      The aim of an adapted surgical prehabilitation program is to improve the functional recovery&#xD;
      of the treated limb and the patient's autonomy after surgery.&#xD;
&#xD;
      Each patient will be followed until 24 months post surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with a MSTS score (Musculoskeletal Tumor Rating Scale) greater than 75% at 24 months post-surgery.</measure>
    <time_frame>24 months for each patient.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life using the Quality Of Life Questionnaire Core 30 (QLQ-C30).</measure>
    <time_frame>24 months for each patient.</time_frame>
    <description>Quality of life will be evaluated from OTE1 to OTE8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety using the Hospital Anxiety and Depression Scale (HADS).</measure>
    <time_frame>24 months for each patient.</time_frame>
    <description>Seven item subscale. Each item is scored on a 4-point scale. Anxiety will be evaluated from OTE1 to OTE8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression using the Hospital Anxiety and Depression Scale (HADS).</measure>
    <time_frame>24 months for each patient.</time_frame>
    <description>Seven item subscale. Each item is scored on a 4-point scale. Depression will be evaluated from OTE1 to OTE8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient functionality will be evaluated using the Tinetti's test from OTE1 to OTE8.</measure>
    <time_frame>24 months for each patient.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient functionality will be evaluated using the 6-min walk test from OTE1 to OTE8.</measure>
    <time_frame>24 months for each patient.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient functionality will be evaluated using the New Functional Ambulation Classification test from OTE1 to OTE8.</measure>
    <time_frame>24 months for each patient.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient functionality will be evaluated using the Box and Block Test from OTE1 to OTE8.</measure>
    <time_frame>24 months for each patient.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient functionality will be evaluated using the Frenchay Arm Test from OTE1 to OTE8.</measure>
    <time_frame>24 months for each patient.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient functionality will be evaluated using the Visual Analog Scale from OTE1 to OTE8.</measure>
    <time_frame>24 months for each patient.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient functionality will be evaluated using the Ricci and Gagnon's Score from OTE1 to OTE8.</measure>
    <time_frame>24 months for each patient.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Patients treated for bone or soft-tissue sarcoma of the limbs</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Surgical prehabilitation program.</intervention_name>
    <description>This programme will include the practice of general physical activity and the implementation of nutritional and psychological support.&#xD;
Each patient will have 8 Oncorehabilitation Transdisciplinary Evaluations (OTE):&#xD;
2 OTE will be performed before the surgery,&#xD;
6 OTE will be performed after the surgery.&#xD;
During the program (at each OTE), patients will also be asked to complete the QLQ-C30 questionnaire.</description>
    <arm_group_label>Patients treated for bone or soft-tissue sarcoma of the limbs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; or = 16 years old.&#xD;
&#xD;
          2. Patient with a diagnosis of bone or soft-tissue sarcoma confirmed by the &quot;RÃ©seau de&#xD;
             Relecture en Pathologie Sarcomateuse (RRePS)&quot;&#xD;
&#xD;
          3. Tumour localized in the lower or upper limb.&#xD;
&#xD;
          4. Localized or metastatic disease (in case of metastatic disease, the optimal surgical&#xD;
             treatment for the primary tumor must be performed).&#xD;
&#xD;
          5. Indication of neoadjuvant treatment (radiotherapy and/or chemotherapy) according to&#xD;
             the Multidisciplinary Concertation Meeting.&#xD;
&#xD;
          6. Inclusion before the initiation or during neoadjuvant treatment. In both cases,&#xD;
             surgery must be scheduled between 6 and 10 weeks after inclusion, to permit the&#xD;
             completion of the surgical prehabilitation.&#xD;
&#xD;
          7. Patient must provide written informed consent prior to any study-specific procedure.&#xD;
             For minor patients, the holder(s) of parental authority must sign the informed consent&#xD;
             and the patient's assent must be obtained.&#xD;
&#xD;
          8. Patient affiliated to the French social security system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastatic disease without optimal surgery planned of the primary tumour.&#xD;
&#xD;
          2. Any disease or medical condition that could interfere with study procedure, or that&#xD;
             could, according to the judgment of investigator, expose the patient to an&#xD;
             unacceptable risk.&#xD;
&#xD;
          3. Patient who has forfeited his/her freedom by administrative or legal award or who is&#xD;
             under legal protection (curatorship and guardianship, protection of justice).&#xD;
&#xD;
          4. Any psychological, familial, geographic or social situation preventing compliance with&#xD;
             the medical monitoring and/or with study procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dimitri GANGLOFF</last_name>
    <phone>05 31 15 53 58</phone>
    <email>gangloff.dimitri@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri GANGLOFF</last_name>
      <phone>05 31 15 53 58</phone>
      <email>gangloff.dimitri@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone sarcoma</keyword>
  <keyword>Soft-tissue sarcoma</keyword>
  <keyword>Pre-operative prehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

